Get the Stockscreener App
25.05
0.22%
-15.91
After Hours:
25.05
-0.000100
-0.00%
Flexion Therapeutics, Inc. stock is traded at $25.05, with a volume of 4,261.
It is down -0.22% in the last 24 hours and down -2.04% over the past month.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
See More
Previous Close:
$9.14
Open:
$25.07
24h Volume:
4,261
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-13.32
EPS:
-1.88
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
-2.04%
6M Performance:
+10.95%
1Y Performance:
-15.87%
1-Day Range:
$25.03
$25.07
1-Week Range:
$25.03
$25.07
52-Week Range:
$25.03
$25.07
Flexion Therapeutics, Inc. Stock (FLXN) Company Profile
Name
Flexion Therapeutics, Inc.
Sector
Phone
781-305-7777
Address
10 Mall Road, Suite 301, Burlington
Compare FLXN vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLXN
Flexion Therapeutics, Inc.
|
25.05 | 0 | 0 | 0 | 0 | 0.00 |
TAK
Takeda Pharmaceutical Co Adr
|
15.84 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.95 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.21 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.84 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
544.33 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Aug-20-20 | Initiated | Goldman | Neutral |
| Jul-31-20 | Initiated | Oppenheimer | Outperform |
| Jul-29-20 | Initiated | Credit Suisse | Outperform |
| Jun-25-20 | Initiated | H.C. Wainwright | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Dec-27-19 | Reiterated | The Benchmark Company | Buy |
| Dec-05-19 | Initiated | Craig Hallum | Buy |
| Nov-25-19 | Initiated | BTIG Research | Buy |
| May-09-19 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-04-19 | Reiterated | Needham | Buy |
| Jan-04-19 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-28-18 | Initiated | The Benchmark Company | Buy |
| Oct-09-17 | Reiterated | Needham | Buy |
| Aug-24-17 | Initiated | Northland Capital | Outperform |
| Dec-22-16 | Initiated | Raymond James | Strong Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| Jul-21-16 | Initiated | Lake Street | Buy |
| May-03-16 | Resumed | Wells Fargo | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Sep-09-15 | Reiterated | Needham | Buy |
View All
Flexion Therapeutics, Inc. Stock (FLXN) Latest News
Osteoarthritis Therapeutics Market Size & Share | Forecast Report 2035 - Research Nester
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - The Manila Times
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com Australia
Tempest Therapeutics appoints two directors to board - Investing.com UK
Tempest Therapeutics (NASDAQ: TPST) CFO to depart while two independent directors join board - Stock Titan
Osteoarthritis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma - Barchart.com
FLXN Stock Price, Quote & Chart | HORIZON FLEXIBLE INCOME ETF (NYSEARCA:FLXN) - ChartMill
Top Players and Competitive Dynamics in the Osteoarthritis Therapeutics Market - openPR.com
Knee Osteoarthritis Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com
Versant Side Fund III L P Net WorthInsider Trades and Bio as of Apr 23, 2026 - Benzinga
Analysis of Key Market Segments Driving the Joint Pain Injections Market - openPR.com
Flexion Therapeutics, Inc.Common Stock (NY: FLXN - The Chronicle-Journal
Akin Advises Pharmakon in $100 Million Debt Financing for Paratek Pharmaceuticals and Radius Health Combination - Akin
Paratek Pharmaceuticals to Combine with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform - Sixth Street
Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals
Intra-Articular Injections Market Size to Hit USD 13.65 Billion by 2035 - Precedence Research
Joint Pain Injections Market Overview and Leading Players: - openPR.com
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - Finviz
Meredith Marlin Appointed as SVP, Total Rewards at Regeneron - hrtoday.in
Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (... - ADVFN
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates - ADVFN
Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release... - ADVFN
Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (... - ADVFN
Osteoarthritis Therapeutics Market Size to Hit USD 26.31 billion by 2035 - Precedence Research
Anti-Inflammatory Therapeutics Market Size to Hit USD 164.44 Bn by 2035 - Precedence Research
Knee Osteoarthritis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Globe and Mail
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - BioSpace
Knee Osteoarthritis Pipeline Analysis 2025: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight - The Globe and Mail
Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade - Fierce Pharma
Non-Opioid Pain Treatment Market Size, Share | CAGR Of 8.1% - Market.us
Knee Osteoarthritis Treatment Market Size, Share | CAGR Of 7.7% - Market.us
Knee Osteoarthritis Injectable Treatments Market Size to Hit USD 6.78 Billion by 2035 - Precedence Research
Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033 - Precedence Research
Flexion Therapeutics (NASDAQ:FLXN) - intelligentinvestor.com.au
Syncromune Appoints Kerri-Ann Millar as Chief Financial Officer - citybiz
Catalyst Pharmaceuticals Appoints Dr. William T. Andrews as Chief Medical Officer | CPRX Stock News - Quiver Quantitative
Anti-Inflammatory Therapeutics Market Size, Value & Trends | By 2033 - Straits Research
Osteoarthritis Therapeutics Market Size [2033] Report - SkyQuest Technology
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire
From bench to bedside: Osteoarthritis gene therapy developed in the lab at Baylor is in clinical trials nationwide - Baylor College of Medicine Blog Network -
Gene Therapies For Rare Diseases Market Share, Size, Growth and Forecast to 2031 - Insightace Analytic
Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial Officer - GlobeNewswire
Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire
Osteoarthritis Treatment Market 2032: FDA Approvals, Clinical - openPR.com
Pacira BioSciences Reports Second Quarter 2024 Financial Results - GlobeNewswire
Avalo Therapeutics Appoints Dr. Mittie Doyle as Chief Medical Officer - citybiz
Boston Pharmaceuticals Appoints Dr. Margaret Koziel as Chief Medical Officer - citybiz
Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 | DelveInsight - PR Newswire
Ocular Therapeutix Appoints Steve Meyers as Chief Commercial Officer - citybiz
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs - GlobeNewswire
Flexion Therapeutics, Inc. Stock (FLXN) Financials Data
There is no financial data for Flexion Therapeutics, Inc. (FLXN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.45%
3.01%
Cap:
|
Volume (24h):